article thumbnail

Projection Estimates GLP-1 Market to Nearly Double by End of Decade | Asembia 2025

Drug Topics

Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.

article thumbnail

Should Pharmacies Keep Compounding GLP1s?

DiversifyRx

Should You Keep Compounding GLP1s (Tirzepatide or Semaglutide) After the FDA Deadline? Howdy pharmacy peeps… Lets have a real talk about compounding GLP1s. These compounds have been huge revenue drivers and powerful tools for helping patients lose weight and improve metabolic health. Here’s My Take. But others?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Compounded semaglutide with B12: Benefits and risks

The Checkup by Singlecare

However, due to the shortage, compounding pharmacies and facilities were allowed to temporarily produce compounded semaglutide to meet the high demandeven though compounded semaglutide injections are not FDA approved. Some facilities add B12 to their compounds, in addition to semaglutide.

article thumbnail

Pharmacy Law and Licensing Highlights 2025

The FDA Law Blog

By Sara M Keup In reviewing some new 2025 pharmacy rules/laws a couple interesting changes caught this bloggers attention: As of December 30, 2024, Missouri has rolled out new rules related to prescription drug delivery requirements. Massachusetts will begin enforcement against non-licensed pharmacy dispensing beginning on May 1, 2025.

article thumbnail

Mounjaro generic availability, cost, and more

The Checkup by Singlecare

Read on to learn when to expect a generic for Mounjaro , the difference between compounded tirzepatide and a true generic, and how to save on Mounjaro until a generic version becomes available. What’s the difference between Mounjaro and compounded tirzepatide? So, why is compounded tirzepatide even available? mg per week.

article thumbnail

Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’

pharmaphorum

That spend is due to reach of $3 billion by 2025, according to GlobalData analyst Kitty Whitney, who notes that there has been a steady stream of startups formed in the last three to four years to tap into the emerging AI market. The post Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’ appeared first on.

article thumbnail

Major drug compounder is spending millions on misleading Super Bowl ad

PhRMA

One of the largest compounders in the U.S., Hims & Hers, is spending millions of dollars to run a misleading Super Bowl ad that misrepresents their unapproved GLP-1 medicines.